BD311 / BDgene - LARVOL DELTA

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Shanghai BDgene Co., Ltd. | Recruiting ➔ Active, not recruiting | N=18 ➔ 3 | Trial completion date: Sep 2023 ➔ Sep 2025 | Trial primary completion date: Sep 2023 ➔ Nov 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration